<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2026-4-44-49</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2900</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>The search for polyphenolic inhibitors of BTK (Bruton’s tyrosine kinase) for the treatment of multiple sclerosis using machine learning methods</article-title><trans-title-group xml:lang="ru"><trans-title>Поиск полифенольных ингибиторов BTK (тирозинкиназы Брутона) для терапии рассеянного склероза с использованием методов машинного обучения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3682-6571</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Роговский</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Rogovskii</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Станиславович Роговский</p><p>Отдел нейроиммунологии Института клинической неврологии ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России;</p><p>Кафедра молекулярной фармакологии и радиобиологииим. П.В. Сергеева ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» </p><p>117997, Москва, ул. Островитянова, 1, стр. 10,</p><p>117997, Москва, ул. Островитянова, 1</p><p> </p></bio><bio xml:lang="en"><p>Vladimir Stanislavovich Rogovskii</p><p>Department of Neuroimmunology, Institute of Clinical Neurology, Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia;</p><p>Department of Molecular Pharmacology and Radiobiology named after P.V. Sergeev N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</p><p>1, Ostrovityanova St., Build. 10, Moscow 117997, </p><p>1, Ostrovityanova St., Moscow 117997</p></bio><email xlink:type="simple">qwer555@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9964-8103</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кукушкина</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kukushkina</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Отдел нейроиммунологии Института клинической неврологии</p><p>117997, Москва, ул. Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>Department of Neuroimmunology, Institute of Clinical Neurology</p><p>1, Ostrovityanova St., Build. 10, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2975-4151</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Отдел нейроиммунологии Института клинической неврологии ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России</p><p>Кафедра неврологии, нейрохирургии и медицинской генетики ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»</p><p>117997, Москва, ул. Островитянова, 1, стр. 10,</p><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Department of Neuroimmunology, Institute of Clinical Neurology, Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia;</p><p>Department of Neurology, Neurosurgery and Medical Genetics N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</p><p>1, Ostrovityanova St., Build. 10, Moscow 117997, </p><p>1, Ostrovityanova St., Moscow 117997</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России;&#13;
кафедра молекулярной фармакологии и радиобиологии&#13;
им. П.В. Сергеева;&#13;
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia;&#13;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России;&#13;
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia;&#13;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>18</day><month>08</month><year>2026</year></pub-date><volume>18</volume><issue>4</issue><fpage>44</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Rogovskii V.S., Kukushkina A.D., Boyko A.N., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Роговский В.С., Кукушкина А.Д., Бойко А.Н.</copyright-holder><copyright-holder xml:lang="en">Rogovskii V.S., Kukushkina A.D., Boyko A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2900">https://nnp.ima-press.net/nnp/article/view/2900</self-uri><abstract><sec><title>Objective</title><p>Objective: development of a machine learning model to predict the inhibitory activity of natural compounds, predominantly of a polyphenolic nature, against Bruton’s tyrosine kinase (BTK), with the aim of identifying potential candidates for the treatment of multiple sclerosis (MS) with a favourable safety profile.</p></sec><sec><title>Material and methods</title><p>Material and methods. To construct the model, data from the ChEMBL database on BTK inhibitors (CHEMBL5251) were used, containing values for the concentration required to inhibit 50 per cent of the activity (IC50). The IC50 values were converted to the pIC50 format. Molecular structures were represented as ECFP6 fingerprints using the RDKit library. To model the ‘structure–activity’ relationship, the Bayesian Ridge Regression method from the scikit-learn library was applied. Model quality was assessed using the coefficient of determination (R2), as well as Pearson’s and Spearman’s correlation coefficients between the experimental and predicted pIC50 values. The resulting model was used to screen polyphenolic compounds.</p></sec><sec><title>Results</title><p>Results. A machine learning model was developed to predict the inhibitory activity of compounds against BTK. The Pearson and Spearman correlation coefficients between the experimental and predicted pIC50 values were 0.8; the coefficient of determination (R2) was 0.6. In a virtual screening of 21 compounds, rutin demonstrated the highest predicted activity among the polyphenols (predicted IC50 – 24 nM). High predicted BTK inhibitory activity was also identified for luteolin, baicalein, epicatechin and quercetin.</p></sec><sec><title>Conclusion</title><p>Conclusion. Machine learning methods represent a promising tool for identifying new BTK inhibitors amongst natural compounds. The results obtained indicate the potential ability of a number of polyphenols to inhibit BTK and confirm the value of further experimental investigation of these compounds as candidates for the treatment of MS.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Цель исследования – разработка модели машинного обучения, позволяющей прогнозировать ингибирующую активность природных соединений, преимущественно полифенольной природы, в отношении тирозинкиназы Брутона (Bruton tyrosine kinase, BTK) для поиска потенциальных кандидатов для терапии рассеянного склероза (РС) с благоприятным профилем безопасности.</p><sec><title>Материал и методы</title><p>Материал и методы. Для построения модели использовали данные базы ChEMBL по ингибиторам BTK (CHEMBL5251), содержащие значения концентрации, вызывающей 50% ингибирование активности (IC50). Значения IC50 переводили в формат pIC50. Молекулярные структуры представляли в виде отпечатков ECFP6 с использованием библиотеки RDKit. Для моделирования взаимосвязи «структура – активность» применяли метод Bayesian Ridge Regression библиотеки scikit-learn. Качество модели оценивали с использованием коэффициента детерминации (R2), а также коэффициентов корреляции Пирсона и Спирмена между экспериментальными и предсказанными значениями pIC50. Полученная модель использовалась для скрининга полифенольных соединений.</p></sec><sec><title>Результаты</title><p>Результаты. Построена модель машинного обучения для прогнозирования ингибирующей активности соединений в отношении BTK. Коэффициенты корреляции Пирсона и Спирмена между экспериментальными и предсказанными значениями pIC50 составили 0,8; коэффициент детерминации R2 составил 0,6. При виртуальном скрининге 21 соединения наибольшую прогнозную активность из полифенолов продемонстрировал рутин (прогнозный IC50 – 24 нМ). Высокие прогнозные показатели ингибирования BTK также выявлены для лютеолина, байкалеина, эпикатехина и кверцетина.</p></sec><sec><title>Заключение</title><p>Заключение. Методы машинного обучения представляют собой перспективный инструмент для поиска новых ингибиторов BTK среди природных соединений. Полученные результаты указывают на потенциальную способность ряда полифенолов ингибировать BTK и подтверждают целесообразность их дальнейшего экспериментального изучения в качестве кандидатов для терапии РС.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>тирозинкиназа Брутона</kwd><kwd>рассеянный склероз</kwd><kwd>полифенолы</kwd><kwd>машинное обучение</kwd><kwd>ингибиторы киназ</kwd><kwd>виртуальный скрининг</kwd><kwd>хемоинформатика</kwd><kwd>природные соединения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Bruton’s tyrosine kinase</kwd><kwd>BTK</kwd><kwd>multiple sclerosis</kwd><kwd>polyphenols</kwd><kwd>machine learning</kwd><kwd>kinase inhibitors</kwd><kwd>virtual screening</kwd><kwd>cheminformatics</kwd><kwd>natural compounds</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Torke S, Weber MS. Inhibition of Bruton s tyrosine kinase as a novel therapeutic approach in multiple sclerosis. Expert Opin Investig Drugs. 2020;29:1143-50. doi: 10.1080/13543784.2020.1807934</mixed-citation><mixed-citation xml:lang="en">Torke S, Weber MS. Inhibition of Bruton s tyrosine kinase as a novel therapeutic approach in multiple sclerosis. Expert Opin Investig Drugs. 2020;29:1143-50. doi: 10.1080/13543784.2020.1807934</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen P, Cross D, Janne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20:551-69. doi: 10.1038/s41573-021-00195-4</mixed-citation><mixed-citation xml:lang="en">Cohen P, Cross D, Janne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20:551-69. doi: 10.1038/s41573-021-00195-4</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-7. doi: 10.1056/NEJM200104053441401</mixed-citation><mixed-citation xml:lang="en">Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-7. doi: 10.1056/NEJM200104053441401</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton's tyrosine kinase in the immune system and disease. Immunology. 2021;164:722-36. doi: 10.1111/imm.13416</mixed-citation><mixed-citation xml:lang="en">McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton's tyrosine kinase in the immune system and disease. Immunology. 2021;164:722-36. doi: 10.1111/imm.13416</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kramer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19:289-304. doi: 10.1038/s41582-023-00800-7</mixed-citation><mixed-citation xml:lang="en">Kramer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19:289-304. doi: 10.1038/s41582-023-00800-7</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Airas L, Bermel RA, Chitnis T, et al. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Ther Adv Neurol Disord. 2024;17:17562864241233041. doi: 10.1177/17562864241233041</mixed-citation><mixed-citation xml:lang="en">Airas L, Bermel RA, Chitnis T, et al. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Ther Adv Neurol Disord. 2024;17:17562864241233041. doi: 10.1177/17562864241233041</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Elkjaer ML, Waede MR, Kingo C, et al. Expression of Bruton s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. Front Immunol. 2023;14:1264128. doi: 10.3389/fimmu.2023.1264128</mixed-citation><mixed-citation xml:lang="en">Elkjaer ML, Waede MR, Kingo C, et al. Expression of Bruton s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. Front Immunol. 2023;14:1264128. doi: 10.3389/fimmu.2023.1264128</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Broccoli A, Del Re M, Danesi R, Zinzani PL. Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. J Cell Mol Med. 2025;29:e70170. doi: 10.1111/jcmm.70170</mixed-citation><mixed-citation xml:lang="en">Broccoli A, Del Re M, Danesi R, Zinzani PL. Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. J Cell Mol Med. 2025;29:e70170. doi: 10.1111/jcmm.70170</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-23. doi: 10.1056/NEJMoa1400376</mixed-citation><mixed-citation xml:lang="en">Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-23. doi: 10.1056/NEJMoa1400376</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fraga CG, Croft KD, Kennedy DO, Tomas-Barberan FA. The effects of polyphenols and other bioactives on human health. Food Funct. 2019;10:514-28. doi: 10.1039/c8fo01997e</mixed-citation><mixed-citation xml:lang="en">Fraga CG, Croft KD, Kennedy DO, Tomas-Barberan FA. The effects of polyphenols and other bioactives on human health. Food Funct. 2019;10:514-28. doi: 10.1039/c8fo01997e</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jeong H, Phan ANH, Choi JW. Anti-cancer Effects of Polyphenolic Compounds in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Pharmacogn Mag. 2017;13:595-9. doi: 10.4103/pm.pm_535_16</mixed-citation><mixed-citation xml:lang="en">Jeong H, Phan ANH, Choi JW. Anti-cancer Effects of Polyphenolic Compounds in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Pharmacogn Mag. 2017;13:595-9. doi: 10.4103/pm.pm_535_16</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dirimanov S, Hogger P. Screening of Inhibitory Effects of Polyphenols on Akt-Phosphorylation in Endothelial Cells and Determination of Structure-Activity Features. Biomolecules. 2019;9(6):219. doi: 10.3390/biom9060219</mixed-citation><mixed-citation xml:lang="en">Dirimanov S, Hogger P. Screening of Inhibitory Effects of Polyphenols on Akt-Phosphorylation in Endothelial Cells and Determination of Structure-Activity Features. Biomolecules. 2019;9(6):219. doi: 10.3390/biom9060219</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Stokes JM, Yang K, Swanson K, et al. A Deep Learning Approach to Antibiotic Discovery. Cell. 2020;180:688-702. doi: 10.1016/j.cell.2020.01.021</mixed-citation><mixed-citation xml:lang="en">Stokes JM, Yang K, Swanson K, et al. A Deep Learning Approach to Antibiotic Discovery. Cell. 2020;180:688-702. doi: 10.1016/j.cell.2020.01.021</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zdrazil B, Felix E, Hunter F, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52:D1180-D1192. doi: 10.1093/nar/gkad1004</mixed-citation><mixed-citation xml:lang="en">Zdrazil B, Felix E, Hunter F, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52:D1180-D1192. doi: 10.1093/nar/gkad1004</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Davies M, Nowotka M, Papadatos G, et al. ChEMBL web services: streamlining access to drug discovery data and utilities. Nucleic Acids Res. 2015;43:W612-20. doi: 10.1093/nar/gkv352</mixed-citation><mixed-citation xml:lang="en">Davies M, Nowotka M, Papadatos G, et al. ChEMBL web services: streamlining access to drug discovery data and utilities. Nucleic Acids Res. 2015;43:W612-20. doi: 10.1093/nar/gkv352</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24:656-66. doi: 10.1016/S1474-4422(25)00174-7</mixed-citation><mixed-citation xml:lang="en">Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24:656-66. doi: 10.1016/S1474-4422(25)00174-7</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclindependent kinases. Nat Cell Biol. 1999;1:60-7. doi: 10.1038/9035</mixed-citation><mixed-citation xml:lang="en">Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclindependent kinases. Nat Cell Biol. 1999;1:60-7. doi: 10.1038/9035</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Boly R, Gras T, Lamkami T, et al. Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol. 2011;38:833-42. doi: 10.3892/ijo.2010.890</mixed-citation><mixed-citation xml:lang="en">Boly R, Gras T, Lamkami T, et al. Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol. 2011;38:833-42. doi: 10.3892/ijo.2010.890</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Oh KS, Oh BK, Park CH, et al. Baicalein potently inhibits Rho kinase activity and suppresses actin stress fiber formation in angiotensin II-stimulated H9c2 cells. Biol Pharm Bull. 2012;35:1281-6. doi: 10.1248/bpb.b12-00121</mixed-citation><mixed-citation xml:lang="en">Oh KS, Oh BK, Park CH, et al. Baicalein potently inhibits Rho kinase activity and suppresses actin stress fiber formation in angiotensin II-stimulated H9c2 cells. Biol Pharm Bull. 2012;35:1281-6. doi: 10.1248/bpb.b12-00121</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y, Bao G, Zhu G, et al. Discovery and characterization of natural product luteolin as an effective inhibitor of human pyridoxal kinase. Bioorg Chem. 2024;143:107057. doi: 10.1016/j.bioorg.2023.107057</mixed-citation><mixed-citation xml:lang="en">Zhu Y, Bao G, Zhu G, et al. Discovery and characterization of natural product luteolin as an effective inhibitor of human pyridoxal kinase. Bioorg Chem. 2024;143:107057. doi: 10.1016/j.bioorg.2023.107057</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Tian H, Zhang Y, Xiao S, et al. Luteolin rescues myelin integrity and cognitive-motor function via Nrf2 pathway activation: a natural candidate vs. dimethyl fumarate in cuprizoneinduced multiple sclerosis. Nutr Neurosci. 2026 Jun;29(6):764-80. doi: 10.1080/1028415X.2025.2599459</mixed-citation><mixed-citation xml:lang="en">Tian H, Zhang Y, Xiao S, et al. Luteolin rescues myelin integrity and cognitive-motor function via Nrf2 pathway activation: a natural candidate vs. dimethyl fumarate in cuprizoneinduced multiple sclerosis. Nutr Neurosci. 2026 Jun;29(6):764-80. doi: 10.1080/1028415X.2025.2599459</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Li X, Ciric B, et al. Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway. Sci Rep. 2015;5:17407. doi: 10.1038/srep17407</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Li X, Ciric B, et al. Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway. Sci Rep. 2015;5:17407. doi: 10.1038/srep17407</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Petracca M, Quarantelli M, Moccia M, et al. ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial. Mult Scler Relat Disord. 2021;56:103274. doi: 10.1016/j.msard.2021.103274</mixed-citation><mixed-citation xml:lang="en">Petracca M, Quarantelli M, Moccia M, et al. ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial. Mult Scler Relat Disord. 2021;56:103274. doi: 10.1016/j.msard.2021.103274</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kukushkina A, Rogovskii V, Zhilenkova O, et al. Anti-Inflammatory Properties of Curcumin as Add-On Therapy in Patients with MS – Prospective, Comparative, Randomized, Pilot Study. Pharmaceutics. 2026;18:519.</mixed-citation><mixed-citation xml:lang="en">Kukushkina A, Rogovskii V, Zhilenkova O, et al. Anti-Inflammatory Properties of Curcumin as Add-On Therapy in Patients with MS – Prospective, Comparative, Randomized, Pilot Study. Pharmaceutics. 2026;18:519.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Dolati S, Ahmadi M, Aghebti-Maleki L, et al. Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators. Pharmacol Rep. 2018;70:1158- 67. doi: 10.1016/j.pharep.2018.05.008</mixed-citation><mixed-citation xml:lang="en">Dolati S, Ahmadi M, Aghebti-Maleki L, et al. Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators. Pharmacol Rep. 2018;70:1158- 67. doi: 10.1016/j.pharep.2018.05.008</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Golonko A, Lewandowska H, Swislocka R, et al. Curcumin as tyrosine kinase inhibitor in cancer treatment. Eur J Med Chem. 2019;181:111512. doi: 10.1016/j.ejmech.2019.07.015</mixed-citation><mixed-citation xml:lang="en">Golonko A, Lewandowska H, Swislocka R, et al. Curcumin as tyrosine kinase inhibitor in cancer treatment. Eur J Med Chem. 2019;181:111512. doi: 10.1016/j.ejmech.2019.07.015</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Muvhulawa N, Dludla PV, Ziqubu K, et al. Rutin ameliorates inflammation and improves metabolic function: A comprehensive analysis of scientific literature. Pharmacol Res. 2022;178:106163, doi: 10.1016/j.phrs.2022.106163</mixed-citation><mixed-citation xml:lang="en">Muvhulawa N, Dludla PV, Ziqubu K, et al. Rutin ameliorates inflammation and improves metabolic function: A comprehensive analysis of scientific literature. Pharmacol Res. 2022;178:106163, doi: 10.1016/j.phrs.2022.106163</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Manach C, Morand C, Demigne C, et al. Bioavailability of rutin and quercetin in rats. FEBS Lett. 1997;409:12-6. doi: 10.1016/s0014-5793(97)00467-5</mixed-citation><mixed-citation xml:lang="en">Manach C, Morand C, Demigne C, et al. Bioavailability of rutin and quercetin in rats. FEBS Lett. 1997;409:12-6. doi: 10.1016/s0014-5793(97)00467-5</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Erlund I, Kosonen T, Alfthan, G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol. 2000;56:545-53. doi: 10.1007/s00228000019</mixed-citation><mixed-citation xml:lang="en">Erlund I, Kosonen T, Alfthan, G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol. 2000;56:545-53. doi: 10.1007/s00228000019</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
